UM-UC-3 Xenograft Model Service for Bladder Cancer

The UM-UC-3 xenograft model represents one of the most aggressive and widely utilized preclinical platforms for muscle-invasive bladder cancer research, enabling robust evaluation of therapeutic efficacy, tumor biology, and metastatic mechanisms. At Alfa Cytology, we specialize in delivering high-quality, reproducible UM-UC-3 xenograft model services tailored to support your preclinical drug development pipeline---from compound screening and pharmacokinetic studies to biomarker discovery and combination therapy assessment---with rigorous quality control, transparent reporting, and flexible study designs that align with your specific research objectives.

Overview of UM-UC-3 Xenograft Model for Bladder Cancer

The UM-UC-3 cell line was originally established from a metastatic lymph node lesion of a male patient diagnosed with poorly differentiated, high-grade transitional cell carcinoma (urothelial carcinoma) of the bladder. Genetically, UM-UC-3 harbors a homozygous deletion of TP53, loss of RB1 and PTEN, and activating HRAS mutations, resulting in constitutive PI3K/AKT pathway activation, impaired DNA damage response, and deregulated cell cycle checkpoints. Phenotypically, the cells exhibit a basal-like, mesenchymal profile characterized by high expression of vimentin, N-cadherin, and MMP-9, while lacking epithelial markers such as E-cadherin, uroplakin, and cytokeratin 20---features that closely mirror aggressive, muscle-invasive bladder cancer (MIBC) in the clinical setting.

In vivo, UM-UC-3 xenografts demonstrate rapid and consistent tumor formation with high cellular density, prominent nucleoli, hyperchromatic nuclei, and high mitotic activity. The model recapitulates key histopathological hallmarks of advanced urothelial carcinoma, including muscle-invasive growth patterns, angiogenic activity (elevated VEGF-A and CD31 expression), and metastatic potential to lung, liver, and lymph nodes under orthotopic or specialized co-inoculation conditions. These characteristics make the UM-UC-3 xenograft an indispensable tool for preclinical studies targeting chemoresistance, epithelial-to-mesenchymal transition (EMT), oncogenic signaling, and novel therapeutic strategies in bladder cancer.

Figure 1. Western blot analysis of (A) DeltaNp63 in UM-UC-3 control and siRNA-treated cells (75 kDa) and (B) DeltaNp63 and claudin-1 in UM-UC-3 control and UM-UC-3 cells transfected with si-DeltaNp63 plasmid, negative plasmid or empty vector. (Jing, P, et al., 2013)

Cell Line Information: UM-UC-3

The UM-UC-3 cell line is a well-characterized human bladder carcinoma model with the following detailed specifications:

Our Services

Alfa Cytology offers comprehensive, end-to-end UM-UC-3 xenograft model services designed to accelerate your preclinical bladder cancer research. Our experienced scientific team provides customized study designs encompassing subcutaneous and orthotopic implantation, bioluminescence imaging for real-time tumor monitoring, pharmacodynamic and pharmacokinetic profiling, and detailed histopathological analysis---ensuring reliable, publication-ready data delivered with full transparency and regulatory compliance.

Workflow of UM-UC-3 Xenograft Model Construction

Construction of the UM-UC-3 xenograft model follows a standardized, quality-controlled workflow optimized for high engraftment rates, reproducible tumor growth kinetics, and compatibility with downstream therapeutic and imaging applications. The protocol can be adapted for both subcutaneous (flank) and orthotopic (bladder wall or intravesical) implantation strategies depending on study objectives.

Step 1: Cell Preparation and Quality Control

UM-UC-3 cells are expanded under standardized culture conditions and authenticated via STR profiling. Viability is confirmed by trypan blue exclusion (typically >95% viable), and mycoplasma testing is performed to ensure culture purity. For imaging-enabled studies, cells may be stably transduced with luciferase and/or fluorescent reporters (e.g., GFP) prior to implantation.

Step 2: Mouse Strain Selection and Preparation

Immunodeficient mouse strains are selected based on model requirements. Athymic nude (nu/nu), NOD/SCID, or highly immunodeficient NSG mice are commonly employed. For orthotopic models, SCID-beige mice may be preferred to achieve optimal engraftment rates. Animals are acclimatized, health-monitored, and randomized prior to tumor cell inoculation.

Step 3: Tumor Cell Inoculation

For subcutaneous models, 3 x 10^6 to 6 x 10^6 UM-UC-3 cells are resuspended in serum-free medium (with or without Matrigel) and injected into the flank region using a sterile 25--27 G needle. For orthotopic models, cells are instilled transurethrally via a 24 G catheter (0.5 x 10^6 to 1.0 x 10^6 cells) following bladder pretreatment with poly-L-lysine or trypsin to enhance adherence, with a dwell time of 2 hours to optimize engraftment.

Step 4: Tumor Monitoring and Imaging

Tumor growth is monitored via caliper measurements (subcutaneous) or non-invasive bioluminescence imaging (BLI) for luciferase-tagged models. Orthotopic tumors are additionally assessed by MRI or PET imaging where indicated. Measurements begin upon palpable tumor detection (typically days 7--10) and continue at regular intervals until study endpoints.

Step 5: Treatment Administration and Sampling

Once tumors reach the target volume (e.g., 100--200 mm^3 for subcutaneous; detectable BLI signal for orthotopic), animals are randomized into treatment and control cohorts. Test compounds are administered according to the predefined dosing schedule (e.g., intraperitoneal, intravenous, or intravesical). Body weight and clinical signs are recorded throughout the study period.

Step 6: Endpoint Analysis and Histopathology

At study termination, tumors and relevant organs are harvested, weighed, and processed for downstream analysis. Hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) for Ki-67, CD31, EGFR, alpha-SMA, and human-specific markers, as well as molecular profiling (Western blot, qPCR, RNA-seq) are performed to characterize tumor response and mechanism of action.

Figure 2. UM-UC-3 xenograft model construction workflow.

Case Study-UM-UC-3 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology successfully established subcutaneous and orthotopic UM-UC-3 xenograft cohorts to evaluate a novel targeted therapeutic candidate. Subcutaneous tumors achieved consistent engraftment (>95% take rate) with rapid growth kinetics, enabling pharmacodynamic assessment within a compressed timeline. Orthotopic models demonstrated muscle-invasive growth patterns and local microenvironmental interactions comparable to clinical high-grade urothelial carcinoma. Treatment arms showed dose-dependent tumor growth inhibition and modulation of PI3K/AKT pathway biomarkers, with comprehensive histopathological and molecular data packages delivered to the sponsor. Detailed quantitative results, including tumor volume curves, survival analyses, and biomarker modulation data, are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your UM-UC-3 xenograft model needs ensures access to a scientifically rigorous, client-centric service platform built on technical excellence and operational transparency.

• Proven expertise in bladder cancer xenograft models with extensive experience across subcutaneous, orthotopic, and metastatic model configurations.
• Rigorous cell line authentication, mycoplasma screening, and quality control protocols to ensure data integrity and reproducibility.
• Flexible, customized study designs accommodating diverse therapeutic modalities including small molecules, biologics, antibody-drug conjugates, and combination regimens.
• Integrated in vivo imaging capabilities (BLI, MRI, PET) enabling real-time tumor monitoring and quantitative pharmacodynamic readouts.
• Comprehensive endpoint analysis encompassing histopathology, immunohistochemistry, biomarker profiling, and molecular characterization.
• Dedicated project management with transparent communication, milestone-driven reporting, and adherence to predefined timelines.
• Competitive pricing structures and scalable cohort sizes designed to meet the budgetary and timeline requirements of both early discovery and late-stage preclinical programs.

Contact Us

Ready to advance your bladder cancer preclinical program with our UM-UC-3 xenograft model service? Contact us today to discuss your study requirements, receive a customized proposal, and explore how Alfa Cytology can deliver the reliable, high-quality data you need to drive your therapeutic pipeline forward. Our scientific team is standing by to reach out and collaborate with you on your next breakthrough. Please reach out to us today via our inquiry form or email to learn more about our UM-UC-3 Xenograft Model services.

For research use only. Not intended for any clinical use.